文献速递前列腺增生与排尿功能障碍泌尿系感染

非侵入性膀胱内灌注A型肉毒毒素治疗膀胱过度活动症及间质性膀胱炎/膀胱疼痛综合征的系统评价与Meta分析

Efficacy and Safety of Noninvasive Intravesical Instillation of Onabotulinum Toxin-A for Overactive Bladder and Interstitial Cystitis/Bladder Pain Syndrome: Systematic Review and Meta-analysis.
PubMed 文献 · Urology · 2018-12-12

该系统评价与Meta分析纳入4项研究共6项试验(248例患者,实验组121例、对照组127例),评估非侵入性膀胱内灌注A型肉毒毒素(OBTX-A)治疗膀胱过度活动症和间质性膀胱炎/膀胱疼痛综合征的疗效与安全性。结果显示灌注OBTX-A较安慰剂显著增加排尿量(均数差38.48,95%CI:76.05,0.92),其他结局指标无统计学显著变化,未报告重大不良事件。结论认为该方法疗效有限,仅排尿量有改善。

要点

  • 非侵入性膀胱内灌注OBTX-A较安慰剂显著增加排尿量,均数差38.48(95%CI:76.05,0.92)。
  • 尿急发作、排尿频率、急迫性尿失禁等其他结局指标无统计学显著变化。
  • 灌注组未报告重大不良事件,但整体疗效有限,需更多研究改进药物转运。

核心结论

  • 非侵入性膀胱内灌注OBTX-A治疗膀胱过度活动症或间质性膀胱炎/膀胱疼痛综合征疗效有限,仅排尿量有改善。

研究设计与样本

  • 系统评价与Meta分析,最终纳入4项研究中的6项试验,共248例患者(实验组121例、对照组127例),比较OBTX-A灌注与安慰剂。

主要发现

  • 灌注OBTX-A较安慰剂显著增加排尿量,均数差38.48(95%CI:76.05,0.92)。
  • 每72小时尿急发作次数、每72小时排尿频率、急迫性尿失禁、残余尿量、最大尿流率及患者膀胱状况感知等结局无统计学显著变化。
  • 接受膀胱内灌注OBTX-A的组未报告重大不良事件。

关键数值与推荐

  • 排尿量均数差38.48(95%CI:76.05,0.92),对象为膀胱过度活动症或间质性膀胱炎/膀胱疼痛综合征患者。

临床怎么用

  • 当前证据下非侵入性膀胱内灌注OBTX-A仅对排尿量有有限改善,其他症状结局未显获益,临床应用需谨慎评估。

局限性

  • 纳入研究数量有限(4项研究中的6项试验),样本量248例,其他结局指标无显著变化,药物转运效率问题尚未解决。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the efficacy and safety of noninvasive intravesical instillation of onabotulinum toxin-A (OBTX-A) through systematic review and meta-analysis. Recently, several studies of noninvasive intravesical instillation of OBTX-A have been published. However, its efficacy is not well validated yet compared to well-known efficacy of minimally invasive intravesical injection of OBTX-A. METHOD: Systematic review and meta-analysis were performed to evaluate the efficacy of noninvasive intravesical instillation of OBTX-A in patients with overactive bladder and interstitial cystitis/bladder pain syndrome by measuring outcomes such as urgency episode per 72 hours, frequency per 72 hours, urgency urinary incontinence, voided volume (VV), postvoided residual volume, maximum flow rate, and patient perception of bladder condition. RESULT: Six trials in 4 studies that compared instillation of OBTX-A and placebo involving 248 patients (121 experimental and 127 controls) were included for final data extraction. Instillation of OBTX-A significantly increased VV, with a mean difference of 38.48 (95% confidence interval: 76.05, 0.92) compared to the placebo group. However, other outcomes showed statistically insignificant changes. Major adverse events were not reported in the group receiving intravesical instillation of OBTX-A. CONCLUSION: Intravesical instillation of OBTX-A showed limited efficacy with improvement of VV for treatment of overactive bladder or interstitial cystitis/bladder pain syndrome. More studies are needed to overcome the efficacy of current noninvasive bladder instillation of OBTX-A regarding effective drug transport.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Lee HY, Doo SW, Yang WJ, et al. Efficacy and Safety of Noninvasive Intravesical Instillation of Onabotulinum Toxin-A for Overactive Bladder and Interstitial Cystitis/Bladder Pain Syndrome: Systematic Review and Meta-analysis. Urology. 2018. PMID: 30552935. doi:10.1016/j.urology.2018.11.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。